Welcome to our dedicated page for Orasure Tech news (Ticker: OSUR), a resource for investors and traders seeking the latest updates and insights on Orasure Tech stock.
OraSure Technologies Inc. develops, manufactures and distributes point-of-need and home diagnostic tests, along with sample collection and stabilization products used in healthcare and research settings. Its portfolio includes rapid diagnostic tests and sample management solutions sold to clinical laboratories, hospitals, physicians' offices, clinics, public health and community organizations, research institutions, government agencies, pharmaceutical companies and consumers.
OraSure news commonly covers quarterly results, manufacturing efficiency, product regulatory updates, commercial launches, research and development priorities, and capital allocation. Company updates also address subsidiaries including DNA Genotek, Sherlock Biosciences and BioMedomics, products such as OraQuick HIV self-testing and Colli-Pee urine collection, and governance matters involving board composition and shareholder engagement.
OraSure Technologies (NASDAQ: OSUR) has launched HEMAcollect™●PROTEIN, a novel blood collection device designed for proteomic research. The product, developed by subsidiary DNA Genotek, features an evacuated blood collection tube with proprietary stabilizing technology that can preserve plasma proteins in whole blood for up to seven days at ambient temperature.
The device, powered by ProteoPrecision™ technology, minimizes hemolysis and platelet activation, ensuring sample integrity. It is compatible with various proteomic technologies including mass spectrometry, immunoassays, and high-throughput affinity-based platforms. The product aims to support research applications across multiple fields including oncology, neurology, cardiology, and metabolic disorders.
OraSure Technologies (NASDAQ: OSUR) reported Q1 2025 financial results with total net revenues of $29.9 million, down 45% from $54.1 million in Q1 2024. The decline was primarily due to a 98% decrease in COVID-19 revenues following the completion of a major government contract. Core revenues decreased 2% to $29.5 million, with Diagnostics revenues up 8% to $17.7 million but Sample Management Solutions down 16% to $9.1 million.
The company reported a GAAP operating loss of $17.8 million compared to a $7.1 million loss in Q1 2024. The Board authorized a $40 million stock repurchase program over two years. OraSure maintains a strong cash position with $248 million in cash and cash equivalents. For Q2 2025, the company expects revenues between $28.5-32.5 million.
OraSure Technologies (NASDAQ: OSUR) has announced it will release its first quarter 2025 financial results on May 7th, 2025 at 5 p.m. ET. The company will host an earnings conference call to discuss Q1 2025 results and business developments.
A webcast of the conference call will be accessible through OraSure's investor relations website. The webcast recording will remain available for approximately one year after the call. Participants wishing to ask questions during the call must pre-register through the provided registration link.
OraSure Technologies (NASDAQ: OSUR) has announced a significant stock repurchase program authorized by its Board of Directors. The program allows for the repurchase of up to $40 million of common stock over a 24-month period, to be funded from cash on hand.
The company, which specializes in point-of-need and home diagnostic tests and sample management solutions, will implement the repurchase through various methods in compliance with securities laws. Management retains discretion over the amount and timing of share repurchases, with the ability to modify, suspend, or discontinue the program without prior notice.
OraSure Technologies (NASDAQ: OSUR) reported Q4 2024 financial results showing total net revenues decreased 51% to $37.4 million from $75.9 million in Q4 2023, primarily due to declining COVID-19 revenues. Core revenues increased 10% year-over-year to $36.5 million, with Diagnostics revenues up 9% to $18.8 million and Sample Management Solutions up 14% to $14.8 million.
The company reported a GAAP operating loss of $12.4 million compared to operating income of $3.9 million in Q4 2023. Cash and cash equivalents stood at $267.8 million. Notable developments include the acquisition of Sherlock Biosciences to expand molecular diagnostics capabilities, FDA approval for expanded age range of OraQuick HIV Self-Test, and a $7.5 million BARDA contract for Marburg Virus Disease test development. The company guides Q1 2025 revenues between $27.5-31.5 million.
OraSure Technologies (NASDAQ: OSUR) has scheduled its Q4 2024 earnings conference call for February 25, 2025, at 5 p.m. ET. The company will discuss fourth quarter financial results and business developments during the call.
A webcast will be available on OraSure's investor relations website, with registration required at least 10 minutes before the call. The webcast recording will be accessible for approximately 90 days after the event. Participants who wish to ask questions during the call must pre-register through a provided link to receive access details.
OraSure Technologies (NASDAQ: OSUR), a leading provider of point-of-need and home diagnostic tests and sample management solutions, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team will deliver their presentation on Thursday, January 16, 2025, at 9:00 a.m. PT.
Interested parties can access both a live webcast and replay of the presentation through the 'Events and Presentations' section of OraSure's investor relations website. This significant healthcare industry event provides OraSure an opportunity to showcase its developments and strategies to investors and healthcare professionals.
OraSure Technologies (NASDAQ: OSUR) announced FDA approval for expanding the age range of its OraQuick® HIV Self-Test to include individuals 14 years and older, down from the previous minimum age of 17. This expansion addresses a critical need, as CDC data shows that 19% of new HIV diagnoses in the US occur among those aged 13-24, with only 6% of high school students ever being tested for HIV. Almost half of young people with HIV are unaware of their status.
The OraQuick® HIV Self-Test has been available to US consumers since 2012. The test includes educational materials and care information to help users make informed decisions regardless of results. This approval aims to increase HIV testing accessibility among adolescents and support early connection to care for those testing positive.
OraSure Technologies announced the expansion of its OraQuick® HIV Self-Test approved age range to include individuals 14 years and older, down from the previous minimum age of 17. This development is particularly significant as CDC data shows that 19% of new HIV diagnoses in the United States occur among young people aged 13-24, with only 6% of high school students ever being tested for HIV. Almost half of young people with HIV are unaware of their status.
The OraQuick® HIV Self-Test has been available to U.S. consumers since 2012. The test includes comprehensive educational materials and care information to help users make informed decisions regardless of results. This expansion aims to increase HIV testing accessibility among adolescents and support early connection to care for those who test positive.
OraSure Technologies (NASDAQ: OSUR) has announced the acquisition of Sherlock Biosciences, expanding its diagnostic test portfolio with advanced molecular diagnostics technology. The key acquisition focuses on Sherlock's molecular self-test for Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG), which provides results in under 30 minutes using self-collected swabs.
The CT/NG test is currently in clinical studies with FDA submission expected by end of 2025. Upon regulatory approval, revenue contribution is anticipated to begin in 2026. The total addressable market for CT/NG testing exceeds $1.5 billion. The acquisition also includes Sherlock's pipeline of molecular tests and next-generation platforms, featuring Ambient Temperature Amplification and CRISPR-based technologies.